Genmab A (GMAB) Total Liabilities (2018 - 2026)

Genmab A (GMAB) has reported Total Liabilities for 9 consecutive years, with $6.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 464.37% year-over-year to $6.6 billion; the trailing twelve-month figure through Jun 2026 stood at $6.6 billion (up 464.37% YoY), and the FY2025 full-year result was $7.0 billion, up 450.2% from the prior year.
• Total Liabilities retreated to $6.6 billion in Q2 2026 per GMAB's latest filing, from $6.7 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $7.0 billion in Q4 2025 and bottomed at $129.3 million in Q3 2025.
• Historically, Total Liabilities has averaged $1.8 billion across 5 years, with a median of $403.2 million in 2024.
• The widest YoY moves for Total Liabilities: up 1531.04% in 2025, down 82.6% in 2025.
• Over 5 years, Total Liabilities stood at $239.2 million in 2022, then soared by 44.51% to $345.6 million in 2023, then surged by 145.35% to $848.0 million in 2024, then soared by 728.55% to $7.0 billion in 2025, then declined by 6.66% to $6.6 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $6.6 billion, $6.7 billion, and $7.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.